Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia
Rapid biochemical and structural response to the treatment with infigratinib
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Eflornithine Plus Sulindac Not Superior to Either Drug Alone in FAP
Findings from the phase III study of pharmacological prevention in patients with familial adenomatous polyposis
Overall Survival Significantly Longer with Darolutamide in Non-metastatic CRPC
Findings from the ARAMIS study
Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III Melanoma with BRAF Mutations
Findings from the COMBI-AD study
FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions
FDA also approved a companion diagnostic for pralsetinib
Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14 Skipping Mutation
Findings from the VISION study
Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14 Skipping Mutation
Findings from the GEOMETRY mono-1 study
Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas
Findings of the TRANSCEND study
FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia
Efficacy was investigated in the QUAZAR study
FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with Advanced Cancer
A qualitative next generation sequencing based in vitro diagnostic test analyzes more than 300 genes and genomic signatures
Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre in Vienna
Low SARS-CoV-2 seroprevalence in both, oncology healthcare workers and cancer patients require continuation of strict safety measures
No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib vs Chemotherapy
Final overall survival data from the AURA3 study possibly impacted by a high percentage of treatment crossover